3
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Bioidentical estradiol gel for hormone therapy in menopause

Pages 423-430 | Published online: 10 Jan 2014

References

  • Belchetz PE. Hormonal treatment of postmenopausal women. N. Engl. J. Med.330, 1062–1071 (1994).
  • Porter M, Penney GC, Russel D, Russell E, Templeton A. A population based survey of women’s experience of the menopause. Br. J. Obstet. Gynaecol.103, 1025–1028 (1996).
  • Birge SJ. The use of estrogen in older women. Clin. Geriatr. Med.19, 617–627 (2003).
  • Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet. Gynecol.95, 726–731 (2000).
  • Jackson RD, Wactawski-Wende J, LaCroix AZ et al.; Women’s Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized trial. J. Bone Miner. Res.21(6), 817–828 (2006).
  • Cauley JA, Robbins J, Chen Z et al.; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA290, 1729–1738 (2003).
  • Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA280, 605–613 (1998).
  • Hulley S, Furberg C, Barrett-Connor E et al.; HERS Research Group. HERS II noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA288, 58–66 (2002).
  • Rossouw JE, Anderson GL, Prentice RL et al., and Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
  • Anderson GL, Limacher M, Assaf AR et al.; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA291, 1701–1712 (2004).
  • Hulley SB, Grady D. The WHI estrogen-alone trial: do things look any better? JAMA291, 1769–1771 (2004).
  • Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet362, 419–427 (2003).
  • Ostrzenski A, Ostrzenska KM. WHI clinical trial revisit: imprecise scientific methodology disqualifies the study’s outcomes. Am. J. Obstet. Gynecol.193(5), 1599–1604 (2005).
  • Mastorakos G, Sakkas EG, Xydakis AM, Creatsas G. Pitfalls of the WHIs: Women’s Health Initiative. Ann. NY Acad. Sci.1092, 331–340 (2006).
  • Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA297(13), 1465–1477 (2007).
  • Klaiber EL, Vogel W, Rako S. A critique of the Women’s Health Initiative hormone therapy study. Fertil. Steril.84, 1589–1601 (2005).
  • Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med.343, 522–529 (2000).
  • Ho JY, Chen MJ, Sheu WH et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum. Reprod.21(10), 2715–2720 (2006).
  • Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause14(3), 373–384 (2007).
  • Notelovitz M. Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause. MedGenMed8(1), 85 (2006).
  • Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA289, 537–538 (2003).
  • US Preventive Services Task Force 2005. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions.
  • American College of Obstetricians and Gynecologists. Women’s Health Care Physicians. Executive summary: hormone therapy. Obstet. Gynecol.104, 1S–4S (2004).
  • Ettinger B, Ensrud KE, Wallace R et al. Effects of ultralow-dose trans-dermal estradiol on bone mineral density: a randomized clinical trial. Obstet. Gynecol.104, 443–451 (2004).
  • Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol.24, 571 (2004).
  • Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet. Gynecol.105, 779–787 (2005).
  • Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas57(1), 81–84 (2007).
  • Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol.85, 304–313 (1995).
  • Tanigawara Y. Role of p-glycoprotein in drug disposition. Ther. Drug Monit.22, 137–140 (2000).
  • Johnson JA. Drug target pharmacogenomics: an overview. Am. J. Pharmacogenomics1, 271–281 (2001).
  • Tempfer CB, Schneeberger C, Huber JC. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics5, 57–65 (2004).
  • Hwang CS, Kwak HS, Lim HJ et al. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J. Steroid Biochem. Mol. Biol.101, 246–253 (2006).
  • Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause11, 356–367 (2004).
  • Walker CR. Bioidentical hormone replacement therapy. A natural option for perimenopause and beyond. Adv. Nurse Pract.9, 39–42 (2001).
  • Vining RF, McGinley RA. The measurement of hormones in saliva: possibilities and pitfalls. J. Steroid Biochem.27, 81–94 (1987).
  • Klee GG, Heser DW. Techniques to measure testosterone in the elderly. Mayo Clin. Proc.75, S19–S25 (2000).
  • Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric7, 347–356 (2004).
  • Fraser JS, Wang Y. New delivery systems for hormone replacement therapy. In: Progress in the Management of the Menopause. Wren BG. Parthenon Publishing, London, UK, 58–67 (1997).
  • Jarvinen A, Nykanen S, Paasiniemi L. Absorption and bioavailability of estradiol from a gel, a patch and a tablet. Maturitas32, 103–113 (1999).
  • Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation100, 717–722 (1999).
  • Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med.331, 417–424 (1994).
  • Scarabin PY, Oger E, Plu-Bureau G. Estrogen and thromboembolism risk study group. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet362, 428–42 (2003).
  • Kawano H, Yasue H, Hirai N et al. Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. Int. J. Clin. Pharmacol. Ther.41, 346–353 (2003).
  • Canonico M, Oger E, Plu-Bureau G et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation115(7), 840–845 (2007).
  • Hope S, Rees MCP. Why do British women start and stop hormone replacement therapy? J. Br. Menopause Soc.1, 26–27 (1995).
  • Paoletti AM, Pilia I, Nannipieri F, Biagini C, Melis GB. Comparison of pharmacokinetic profiles of 17β-estradiol gel 0.6 mg/g (Gelestra) with transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state. Maturitas40, 203–209 (2001).
  • Jarvinen A, Granander M, Nykanen S, Laine T, Geurts P, Viitanen A. Steady state pharmacokinetics of oestradiol in postmenopausal women: effects of application area and washing. J. Obstet. Gynecol.104(Suppl.), 14–18 (1997).
  • Bakken K, Eggen AE, Lund E. Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45–64 years. The Norwegian Women and Cancer (NOWAC) study 1997. Acta Obstet. Gynecol. Scand.83, 850–856 (2004).
  • Lehman L, Simes S. Trough serum levels of estradiol, estrone, and estrone sulfate following transdermal application of Bio-E-Gel™. Fertil. Steril.82, S186–S186 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.